Catabasis Pharma (CATB) Stock Price & Overview
NASDAQ:CATB
Current stock price
The current stock price of CATB is 8.54 null. Today CATB is down by -6.97%. In the past month the price increased by 3.89%. In the past year, price decreased by -78.07%.
CATB Key Statistics
- Market Cap
- 33.34M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.90
- Dividend Yield
- N/A
CATB Stock Performance
CATB Stock Chart
CATB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CATB. When comparing the yearly performance of all stocks, CATB is a bad performer in the overall market: 99.04% of all stocks are doing better.
CATB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CATB. CATB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CATB Earnings
CATB Forecast & Estimates
4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.
CATB Groups
Sector & Classification
CATB Financial Highlights
Over the last trailing twelve months CATB reported a non-GAAP Earnings per Share(EPS) of -5.9. The EPS decreased by -175.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -140.05% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CATB Ownership
CATB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 362.808B | ||
| AMGN | AMGEN INC | 15.15 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.79 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CATB
Company Profile
Catabasis Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 20 full-time employees. The company went IPO on 2015-06-25. Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on development and commercialization of therapeutics. The firm's lead product candidate is QLS-215. QLS-215 is a monoclonal antibody designed to inhibit plasma kallikrein for the treatment of hereditary angioedema, or HAE, a rare, debilitating and life-threatening disease. Plasma kallikrein is a critical component of HAE that causes pathologic vascular permeability, vasodilation and excessive tissue swelling. The firm is in the preclinical development for QLS-215 and to initiate a Phase I a clinical trial.
Company Info
IPO: 2015-06-25
Catabasis Pharma
100 High Street, 28th Floor
Boston MASSACHUSETTS 02110 US
CEO: Jill C. Milne
Employees: 20
Phone: 16173491971.0
Catabasis Pharma / CATB FAQ
What does CATB do?
Catabasis Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 20 full-time employees. The company went IPO on 2015-06-25. Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The firm is focused on development and commercialization of therapeutics. The firm's lead product candidate is QLS-215. QLS-215 is a monoclonal antibody designed to inhibit plasma kallikrein for the treatment of hereditary angioedema, or HAE, a rare, debilitating and life-threatening disease. Plasma kallikrein is a critical component of HAE that causes pathologic vascular permeability, vasodilation and excessive tissue swelling. The firm is in the preclinical development for QLS-215 and to initiate a Phase I a clinical trial.
What is the current price of CATB stock?
The current stock price of CATB is 8.54 null. The price decreased by -6.97% in the last trading session.
Does Catabasis Pharma pay dividends?
CATB does not pay a dividend.
What is the ChartMill rating of Catabasis Pharma stock?
CATB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for Catabasis Pharma?
Catabasis Pharma (CATB) has a market capitalization of 33.34M null. This makes CATB a Nano Cap stock.
Who owns Catabasis Pharma?
You can find the ownership structure of Catabasis Pharma (CATB) on the Ownership tab.